Neoadjuvant Treatment of Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

October 31, 2005

Primary Completion Date

September 4, 2013

Study Completion Date

September 4, 2013

Conditions
Breast Cancer
Interventions
DRUG

Doxorubicin

60 mg/m2 IV, bolus once a day every 14 days x 2-4 cycles

DRUG

Cyclophosphamide

600 mg/m2 IV once a day every 14 days x 2-4 cycles

DRUG

Carboplatin

AUC 2 IV weekly for 9-12 doses beginning two weeks after completion of last AC dose

DRUG

Nab-paclitaxel

100 mg/m2 IV over 30 min weekly for 9-12 doses beginning two weeks after completion of last AC dose

DRUG

GM-CSF

250 μg/mL IV or on day 4-13 of each subcutaneous cycle of doxorubicin and injection cyclophosphamide

DRUG

Trastuzumab

4mg/kg, and then2 mg/kg q wk IV weekly for 12-16 doses beginning two weeks after completion of last AC dose

DRUG

Bevacizumab

10mg/kg q 2 wks

Trial Locations (1)

92868

Chao Family Comprehensive Cancer Center, Orange

All Listed Sponsors
lead

University of California, Irvine

OTHER

NCT00254592 - Neoadjuvant Treatment of Breast Cancer | Biotech Hunter | Biotech Hunter